Multiple myeloma staging

Jump to navigation Jump to search

Multiple myeloma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Multiple Myeloma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

Echocardiograph and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Future or Investigational Therapies

Case Studies

Case #1

Multiple myeloma staging On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Multiple myeloma staging

All Images
X-rays
Echo and Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Multiple myeloma staging

CDC on Multiple myeloma staging

Multiple myeloma staging in the news

Blogs on Multiple myeloma staging

Directions to Hospitals Treating Multiple myeloma

Risk calculators and risk factors for Multiple myeloma staging

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

International Staging System for multiple myeloma, based on β2-microglobulin (β2M) levels and serum albumin levels, was published by International myeloma working group in 2003 and is the most widely used staging system. It is used for both guiding treatment as well as predicting prognosis.

Staging

International Staging System

The International Staging System (ISS) for myeloma was published by the International Myeloma Working Group in 2003 [1]:

  • Stage I: β2-microglobulin (β2M) < 3.5 mg/L, albumin >= 3.5 g/dL
  • Stage II: β2M < 3.5 and albumin < 3.5; or β2M between 3.5 and 5.5
  • Stage III: β2M > 5.5
Durie-Salmon staging system

First published in 1975, the Durie-Salmon staging system [2] is still in use, but has largely been superseded by the simpler ISS:

  • stage 1: all of
    • Hb > 10g/dL
    • normal calcium
    • Skeletal survey: normal or single plasmacytoma or osteoporosis
    • Serum paraprotein level < 5 g/dL if IgG, < 3 g/dL if IgA
    • Urinary light chain excretion < 4 g/24h
  • stage 2: fulfilling the criteria of neither 1 nor 3
  • stage 3: one or more of
    • Hb < 8.5g/dL
    • high calcium > 12mg/dL
    • Skeletal survey: 3 or more lytic bone lesions
    • Serum paraprotein >7g/dL if IgG, > 5 g/dL if IgA
    • Urinary light chain excretion > 12g/24h

Stages 1, 2 and 3 of the Durie-Salmon staging system can be divided into A or B depending on serum creatinine:

  • A: serum creatinine < 2mg/dL (< 177 umol/L)
  • B: serum creatinine > 2mg/dL (> 177 umol/L)

References

  1. Greipp PR, San Miguel J, Fonseca R, Avet-Loiseau H, Jacobson JL, Rasmussen E, Crowley J, Durie BMG. Development of an international prognostic index (IPI) for myeloma: report of the international myeloma working group. Hematology Journal 2003;4:S42. NLM ID 100965523.
  2. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 1975;36:842–854. PMID 1182674.


Template:WikiDoc Sources